| Recruiting | A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using NCT06507748 | National Cancer Institute (NCI) | N/A |
| Recruiting | Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Eg NCT07221331 | AstraZeneca | — |
| Recruiting | Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofi NCT06880991 | National Cancer Institute (NCI) | — |
| Recruiting | A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis NCT06541847 | Healx Limited | Phase 2 |
| Recruiting | Neurofibromatosis Type 1 Tumor Early Detection Study NCT06515860 | David Miller | — |
| Withdrawn | Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Stud NCT05825365 | AstraZeneca | Phase 2 |
| Recruiting | Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnet NCT04763109 | Nicole Baca | N/A |
| Active Not Recruiting | PASS of Paediatric Patients Initiating Selumetinib NCT05388370 | AstraZeneca | — |
| Enrolling By Invitation | Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 NCT05238909 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Active Not Recruiting | Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years W NCT05309668 | AstraZeneca | Phase 1 / Phase 2 |
| Completed | Molecular Aspects of Preimplantation Genetic Diagnosis for NF1 NCT05149469 | University Hospital, Strasbourg, France | — |
| Active Not Recruiting | Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adole NCT05101148 | AstraZeneca | Phase 1 |
| Active Not Recruiting | Natural History Study of Cutaneous Neurofibromas in People With NF1 NCT05581511 | Johns Hopkins University | — |
| Completed | Selumetinib Paediatric NF1 Japan Study NCT04495127 | AstraZeneca | Phase 1 |
| Completed | Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis NCT04153344 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Gra NCT03871257 | National Cancer Institute (NCI) | Phase 3 |
| Unknown | Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest NCT05186870 | Guy's and St Thomas' NHS Foundation Trust | — |
| Active Not Recruiting | Pediatric Long-Term Follow-up and Rollover Study NCT03975829 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours NCT03326388 | Great Ormond Street Hospital for Children NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | Whole-body Vibration in Children With Neurofibromatosis Type 1 NCT03888248 | Manchester University NHS Foundation Trust | N/A |
| Completed | Frameshift Peptides of Children With NF1 NCT04212351 | Children's National Research Institute | — |
| Terminated | US Selumetinib Registry NCT05683678 | Alexion Pharmaceuticals, Inc. | — |
| Unknown | Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndro NCT03757247 | Medical University Innsbruck | — |
| Active Not Recruiting | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia NCT03190915 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children NCT03518710 | University Hospital, Toulouse | N/A |
| Recruiting | FARD (RaDiCo Cohort) (RaDiCo-FARD) NCT05954416 | Institut National de la Santé Et de la Recherche Médicale, France | — |
| Completed | Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas NCT03231306 | University of Alabama at Birmingham | Phase 2 |
| Completed | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma NCT02839720 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Familial Investigations of Childhood Cancer Predisposition NCT03050268 | St. Jude Children's Research Hospital | — |
| Completed | Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot NCT02700230 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Interventions for Reading Disabilities in NF1 NCT02964884 | Vanderbilt University | Phase 2 |
| Completed | Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 NCT02944032 | Kristina Hardy | N/A |
| Completed | Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach NCT02777775 | Corewell Health West | — |
| Withdrawn | Stem Cells in NF1 Patients With Tumors of the Central Nervous System NCT03332030 | Roger Packer | — |
| Unknown | Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients NCT02505412 | Tel-Aviv Sourasky Medical Center | — |
| Completed | Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tu NCT02415153 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform N NCT02471339 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Feasibility and Clinically Application of Magnetic Resonance Fingerprinting NCT02387840 | Case Comprehensive Cancer Center | N/A |
| Terminated | Effect of Lamotrigine on Cognition in NF1 NCT02256124 | Erasmus Medical Center | Phase 2 / Phase 3 |
| Unknown | Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1. NCT02078401 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 NCT01851135 | Nantes University Hospital | N/A |
| Terminated | Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma NCT02584413 | Washington University School of Medicine | N/A |
| Completed | Neurofibromatosis Type 1 Brain Tumor Genetic Risk NCT01707836 | Washington University School of Medicine | — |
| Completed | Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pil NCT01553149 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem NCT01626846 | John Jay High School | — |
| Completed | MicroRNAs in Patients With Neurofibromatosis Type 1 NCT01595139 | Ann & Robert H Lurie Children's Hospital of Chicago | — |
| Active Not Recruiting | AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors NCT01362803 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Neurofibromatosis Type 1 Patient Registry NCT01410006 | Washington University School of Medicine | — |
| Completed | Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas NCT01412892 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Unknown | Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs NCT01218152 | KU Leuven | — |
| Completed | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas NCT01125046 | Northwestern University | Phase 2 |
| Completed | Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children W NCT01058330 | Shriners Hospitals for Children | N/A |
| Completed | A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 NCT00853580 | University of Alabama at Birmingham | Phase 2 |
| Completed | Reading Disability in Children With NF1 NCT02397967 | University Hospital, Toulouse | N/A |
| Completed | Functional Imaging and Reading Deficit in Children With NF1 NCT02422732 | University Hospital, Toulouse | N/A |
| Completed | Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 NCT00865644 | Massachusetts General Hospital | Phase 1 |
| Completed | Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I NCT00684398 | National Human Genome Research Institute (NHGRI) | — |
| Completed | A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas NCT00634270 | University of Alabama at Birmingham | Phase 2 |
| Completed | Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 NCT00657202 | Massachusetts General Hospital | EARLY_Phase 1 |
| Active Not Recruiting | Natural History Study of Patients With Neurofibromatosis Type I NCT00924196 | National Cancer Institute (NCI) | — |
| Unknown | Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients NCT01218139 | KU Leuven | — |
| Completed | Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments NCT01445314 | National Cancer Institute (NCI) | — |
| Completed | Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) NCT00844129 | University of Utah | — |
| Completed | Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 NCT00314119 | National Cancer Institute (NCI) | — |
| Completed | Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma NCT00352495 | Children's Oncology Group | Phase 1 |
| Terminated | AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near NCT00326872 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients NCT00667836 | Shriners Hospitals for Children | — |
| Completed | Neurobiology and Treatment of Reading Disability in NF-1 NCT00624234 | Vanderbilt University | N/A |
| Completed | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tum NCT00304083 | Sarcoma Alliance for Research through Collaboration | Phase 2 |
| Completed | Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) NCT00111384 | National Cancer Institute (NCI) | — |
| Completed | Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia NCT00303368 | Shriners Hospitals for Children | — |
| Completed | NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate NCT00169611 | Hospices Civils de Lyon | Phase 4 |
| Completed | Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas NCT00053937 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Ne NCT00060008 | Children's Hospital of Philadelphia | N/A |
| Completed | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study NCT00026780 | National Cancer Institute (NCI) | — |
| Completed | Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas NCT00030264 | Children's Hospital of Philadelphia | Phase 2 |